Replimune (REPL) director awarded 44,500 options at $7.61 exercise price

Rhea-AI Filing Summary

Replimune Group, Inc. director Veleka Peeples-Dyer received a grant of stock options covering 44,500 shares of common stock. The options have an exercise price of $7.61 per share and expire on April 1, 2036. All underlying shares vest on April 1, 2027, making this a compensation-related, non-market transaction.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Peeples-Dyer Veleka

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	44,500	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 44,500 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option shares granted: 44,500 options Exercise price: $7.61 per share Underlying shares: 44,500 shares +3 more

6 metrics

Option shares granted 44,500 options Total stock options awarded to director

Exercise price $7.61 per share Option exercise price for underlying common stock

Underlying shares 44,500 shares Replimune common stock underlying the options

Vesting date April 1, 2027 All underlying shares vest on this date

Expiration date April 1, 2036 Options expire if not exercised by this date

Options held after grant 44,500 options Total options reported following this transaction

Key Terms

Stock Option (right to buy), exercise price, expiration date, underlying security, +2 more

6 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 7.6100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-04-01T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security financial

"underlying_security_title: Common Stock"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

vest financial

"The shares underlying this option vest entirely on April 1, 2027."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Peeples-Dyer Veleka

(Last) (First) (Middle)

C/O REPLIMUNE GROUP, INC.

500 UNICORN PARK DRIVE, SUITE 303

(Street)

WOBURN MASSACHUSETTS 01801

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Replimune Group, Inc. [ REPL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.61	04/01/2026		A		44,500		(1)	04/01/2036	Common Stock	44,500	$0	44,500	D

Explanation of Responses:

1. The shares underlying this option vest entirely on April 1, 2027.

Remarks:

This Form 4 is being filed late due to inadvertent administrative error.

	/s/ Shawn Glidden, attorney-in-fact	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Replimune (REPL) director Veleka Peeples-Dyer report in this Form 4?

The Form 4 shows that director Veleka Peeples-Dyer received a grant of stock options for 44,500 Replimune common shares. These options are compensation-related, not an open-market purchase or sale, and give her the right to buy shares at a fixed exercise price.

How many Replimune (REPL) shares are covered by the new stock options?

The granted stock options cover 44,500 shares of Replimune common stock. This figure represents the total number of underlying shares tied to this specific award and matches the option share count disclosed as outstanding for this grant after the transaction.

What is the exercise price of the new Replimune (REPL) stock options?

The options have an exercise price of $7.61 per share. This means Peeples-Dyer can choose to buy up to 44,500 Replimune common shares at $7.61 each, regardless of the market price, once the options have vested and before they expire.

When do Veleka Peeples-Dyer’s Replimune (REPL) options vest and expire?

All shares underlying this option vest on April 1, 2027. After vesting, the options remain exercisable until their stated expiration date of April 1, 2036, giving a long window for potential exercise, subject to plan and employment terms.

Does this Replimune (REPL) Form 4 reflect an open-market stock purchase or sale?

No, the Form 4 reflects a grant of stock options classified as a grant or award acquisition. It is not an open-market buy or sell transaction; instead, it is part of director compensation, with shares potentially acquired later upon exercise.